Group 1 - Breast cancer has become one of the most common malignant tumors threatening women's health in China, with 357,200 new cases reported in 2022, accounting for 15.6% of all new cancer cases [1] - Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer patients represent a significant portion, approximately 70% of breast cancer cases [1] - Early diagnosis and treatment can lead to better prognosis for patients, but some are diagnosed at advanced stages, leading to a 20%-30% chance of recurrence [1] Group 2 - The introduction of targeted endocrine therapy drugs like CDK4/6 inhibitors has improved the five-year survival rate for patients who experience recurrence and metastasis, although drug resistance remains a challenge [2] - Mutations in the PI3K/AKT/mTOR (PAM) signaling pathway are a major factor in endocrine therapy resistance, prompting recommendations for PAM pathway testing in patients with early recurrence [2] - The accessibility of innovative drugs is a growing concern, with the National Healthcare Security Administration providing strong support for first-in-class targeted innovative drugs based on their mechanisms, clinical benefits, and safety [2] Group 3 - The increasing number of treatment options for late-stage breast cancer patients is expected to enhance the efficiency of healthcare fund allocation and reduce patients' financial burdens [3] - The core principle of innovative drug development is to support true innovation and differentiated innovation, with significant efforts made to include many innovative drugs in the national medical insurance [3] - There is a need for increased public awareness regarding breast cancer subtyping and the importance of molecular classification for precision treatment, alongside promoting early screening and diagnosis [3]